GUILFORD, Conn. — BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 1,020,000 common shares at a price of $0.47 per share to directors of the company. These options vest over a period of 12 months from the date of the grant, expire five years from the date of the grant and are governed by the terms of the company’s stock option plan.
On behalf of the Board of Directors of Bioasis Technologies Inc.
Mark Day, Ph.D., Director and President & Chief Executive Officer
Bioasis Technologies, Inc. is a biopharmaceutical company developing the xB3 TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Richmond, Canada with offices in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20180831005199/en/
Media & Investor Relations:
Bioasis Technologies, Inc.
Catherine London, 917-763-2709